SCHEMBL4819360

SCHEMBL4819360

COC(=O)c1ccc(Oc2ccc(CC(NC(=O)OC(C)(C)C)C(=O)N(C)C)cc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
GRN P28799 2/20 0.44
SORT1 Q99523 2/20 0.44
SCN9A Q15858 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
P2RX3 P56373 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
PTPN1 P18031 3/20 0.40
PTPN22 Q9Y2R2 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
CTSS P25774 5/20 0.39
CTSK P43235 4/20 0.39
BCL2 P10415 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14003076 1.00 LMNA (0.44) LMNAGRNSORT1SCN9AITGB3
SCHEMBL14003078 0.92 GRN (0.47) GRNSORT1SCN9AITGB3ITGA2B
SCHEMBL4610061 0.92 GRN (0.47) GRNSORT1SCN9AITGB3ITGA2B
SCHEMBL4597914 0.90 GRN (0.48) GRNSORT1SCN9AITGB3ITGA2B
SCHEMBL14003081 0.90 GRN (0.48) GRNSORT1SCN9AITGB3ITGA2B
SCHEMBL4819886 0.90 ITGB3 (0.55) LMNAGRNSORT1ITGB3ITGA2B
SCHEMBL14003075 0.90 ITGB3 (0.55) LMNAGRNSORT1ITGB3ITGA2B
SCHEMBL6478751 0.84 LMNA (0.47) LMNAGRNSORT1ITGB3ITGA2B
SCHEMBL6478754 0.84 LMNA (0.47) LMNAGRNSORT1ITGB3ITGA2B
SCHEMBL4826858 0.81 ITGB3 (0.50) ITGB3ITGA2BPPARGPPARAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456292-B2 Hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. (US) 2008-11-25 US disclosed
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives BEXEL PHARMACEUTICALS. INC. 2008-08-21 US disclosed
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives HGFAC, HCAR2, BCAT1 LMNA 3014/4885GRN 3670/4885SORT1 2703/4885
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives HGFAC, HCAR2, BCAT1 LMNA 2960/4885GRN 3309/4885SORT1 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.